Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oncology pharmacist survey: Understanding task value and professional satisfaction.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Same author

Immune-Based Therapies in Pancreatic Cancer: a Systematic Review of Ongoing Clinical Trials (2020-2022).

Journal of gastrointestinal cancer·2025

Same author

Utilizing Simulated Telemedicine Encounters to Conduct Nationwide Studies of Physician Communication Practices.

Journal of palliative medicine·2025

Same author

Phase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer.

Journal of surgical oncology·2025

Same author

BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer.

Med (New York, N.Y.)·2024

Same author

Characterization of undifferentiated carcinomas of the pancreas with and without osteoclast-like giant cells.

JNCI cancer spectrum·2024

Same journal

Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Same journal

Performance evaluation of a two-arm robotic chemotherapy compounding system: Effects of syringe size and compounding cycles on accuracy, efficiency, and safety margins.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Same journal

Impact of community pharmacy-based telephone follow-up on treatment completion in cancer patients receiving adjuvant chemotherapy: A retrospective observational study.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Same journal

Polypharmacy and clinical outcomes in geriatric patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor pathway inhibitors.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Same journal

Therapeutic potential of aspirin in metastatic brain disease: A narrative review bridging evidence from systemic cancers to brain metastasis.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Same journal

Incidence of neutropenia with intrathecal pemetrexed for leptomeningeal disease associated with solid tumors - A retrospective analysis.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 11, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Motor "freezing" with oxaliplatin.

Monica A Patel¹, Rachel L McDevitt², Will Sassack³

¹Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, USA.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners

|March 26, 2021

Summary

This summary is machine-generated.

A patient experienced severe neurological symptoms, including motor slowing and speech difficulty, after oxaliplatin treatment for colon cancer. These symptoms resolved within 24 hours, and future treatments were tolerated with dose adjustments.

Keywords:

Oxaliplatin eloxatin oxalatin toxicity

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

Related Experiment Videos

Last Updated: Nov 11, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing

Published on: September 15, 2023

Area of Science:

Oncology
Neuroscience
Pharmacology

Background:

Oxaliplatin is a common chemotherapy agent used for metastatic colon cancer.
Neurological toxicity is a known side effect of oxaliplatin, but severe acute symptoms are rare.

Observation:

A 52-year-old woman developed acute, severe neurological symptoms after her second oxaliplatin infusion.
Symptoms included profound motor slowing, grip and dorsiflexion deficits, dysarthria, visual impairment, and peripheral paresthesia.

Findings:

The patient's neurological symptoms, described as a "frozen" state, resolved spontaneously within 24 hours without sequelae.
Subsequent oxaliplatin infusions at a reduced dose and slower infusion rate were well-tolerated, with no recurrence of neurological toxicity.

Implications:

This case highlights a rare but severe neurotoxic presentation of oxaliplatin.
Awareness of this potential toxicity is crucial for oncologists to ensure patient safety and optimize treatment regimens.
Management strategies, such as dose reduction and slower infusion, can mitigate neurotoxicity and allow for continued cancer treatment.